565 Effect of non-overlapping mutations in BRAF, NRAS or NF1 on long-term survival after checkpoint inhibitor-based treatment for metastatic melanoma

Similar Items

• Lack of Influence of Non-Overlapping Mutations in <i>BRAF</i>, <i>NRAS</i>, or <i>NF1</i> on 12-Month Best Objective Response and Long-Term Survival after Checkpoint Inhibitor-Based Treatment for Metastatic Melanoma
  by: Alyssa Panning, et al.
  Published: (2023-07-01)
• The Effect of Non-Overlapping Somatic Mutations in <i>BRAF</i>, <i>NRAS</i>, <i>NF1</i>, or <i>CKIT</i> on the Incidence and Outcome of Brain Metastases during Immune Checkpoint Inhibitor Therapy of Metastatic Melanoma
  by: Wolfram Samlowski
  Published: (2024-01-01)
• Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy
  by: Wolfram Samlowski, et al.
  Published: (2021-11-01)
• NRAS and BRAF mutation frequency in primary oral mucosal melanoma
  by: Buery, R.R., et al.
  Published: (2011)
• NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
  by: Philipp Tschandl, et al.
  Published: (2013-01-01)